Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Daiichi Sankyo
Medtronic
Mallinckrodt
UBS
US Army
QuintilesIMS
Healthtrust
Chinese Patent Office

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,992,218

« Back to Dashboard

Which drugs does patent 6,992,218 protect, and when does it expire?

Patent 6,992,218 protects OFIRMEV and is included in one NDA.

Protection for OFIRMEV has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifteen patent family members in fifteen countries.
Summary for Patent: 6,992,218
Title:Method for obtaining aqueous formulations of oxidation-sensitive active principles
Abstract:A method for obtaining aqueous formulations with easily oxidizable active principles, notably phenols, stable over a prolonged period, comprising subjecting them to extreme deoxygenation by bubbling with an inert gas and/or placing wider vaccum, protecting them against possible resorption of oxygen by keeping them under an inert gas atmosphere, by filling, under inert gas, into bottles previously cleared of air by insufflation with inert gas, then subjecting them, while stoppering, to low pressure as obtained in the bottle, of 65,000 Pa maximum, to obtain aqueous solutions having a residual oxygen concentration in the solution below 2 ppm, and preferably of the order of 1 ppm and even 0.5 ppm useful as injectable preparations having an oxygen concentration in the solution below 2 ppm.
Inventor(s): Dietlin; Francois (La Vesinet, FR), Fredj; Daniele (Gif sur Yvette, FR)
Assignee: Pharmatop SCR (FR)
Application Number:10/332,060
Patent Claim Types:
see list of patent claims
Formulation; Process; Use;

Drugs Protected by US Patent 6,992,218

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Mallinckrodt Ip OFIRMEV acetaminophen SOLUTION;IV (INFUSION) 022450-001 Nov 2, 2010 AP RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,992,218

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France00 07231Jun 06, 2000
France00 07231Jun 6, 2000
PCT Information
PCT FiledJune 06, 2001PCT Application Number:PCT/FR01/01749
PCT Publication Date:December 13, 2001PCT Publication Number: WO01/93830

International Patents Family Members for US Patent 6,992,218

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1880 ➤ Sign Up
Australia 6612001 ➤ Sign Up
Canada 2415403 ➤ Sign Up
China 1556694 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Federal Trade Commission
Colorcon
Chinese Patent Office
Merck
Cerilliant
Cipla
US Army
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.